All In Biotech

Drug Trial Radar · NCT05625399

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma

Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 579 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

579

Actual

Start

Mar 6, 2023

Primary completion

Aug 4, 2025

Study completion Nov 18, 2027

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Halozyme Therapeutics
First posted
Nov 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.

Conditions

  • Melanoma

Interventions

  • Nivolumab + RelatlimabDrug

    Specified dose on specified days

  • rHuPH20Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic ScaleTime frame: Pre-dose (Day 1 to Day 28)
  2. Adjusted Time-Averaged Relatlimab Serum Concentration Over the First 28 Days (Cavgd28-Rela) on Natural Logarithmic ScaleTime frame: Pre-dose (Day 1 to Day 28)
  3. Adjusted Trough Nivolumab Serum Concentration at Steady-State (Cminss-Nivo) on Natural Logarithmic ScaleTime frame: Pre-dose (Day 1 to Day 28)
  4. Adjusted Trough Relatlimab Serum Concentration at Steady-State (Cminss-Rela) on Natural Logarithmic ScaleTime frame: Pre-dose (Day 1 to Day 28)

Locations

149 sites in 19 countries. Site status is shown where the registry gives one.

  • Local Institution - 0125

    Phoenix, Arizona

  • Local Institution - 0189

    Springdale, Arkansas

  • Local Institution - 0098

    Los Angeles, California

  • Local Institution - 0093

    Orange, California

  • Local Institution - 0123

    Stanford, California

  • Local Institution - 0113

    Englewood, Colorado

  • Local Institution - 0114

    Jacksonville, Florida

  • Local Institution - 0146

    Baltimore, Maryland

  • Local Institution - 0071

    Rochester, Minnesota

  • Local Institution - 0013

    Omaha, Nebraska

  • Local Institution - 0169

    Cleveland, Ohio

  • Local Institution - 0139

    Easton, Pennsylvania

  • Local Institution - 0124

    Philadelphia, Pennsylvania

  • Local Institution - 0122

    Murray, Utah

  • Local Institution - 0115

    Fairfax, Virginia

  • Local Institution - 0050

    Coffs Harbour, New South Wales, Australia

  • Local Institution - 0175

    Orange, New South Wales, Australia

  • Local Institution - 0172

    Port Macquarie, New South Wales, Australia

  • Local Institution - 0118

    Wagga Wagga, New South Wales, Australia

  • Local Institution - 0184

    Waratah, New South Wales, Australia

  • Local Institution - 0033

    Westmead, New South Wales, Australia

  • Local Institution - 0055

    Wollstonecraft, New South Wales, Australia

  • Local Institution - 0090

    Birtinya, Queensland, Australia

  • Local Institution - 0008

    Bendigo, Victoria, Australia

  • Local Institution - 0059

    Box Hill, Victoria, Australia

  • Local Institution - 0154

    Heidelberg, Victoria, Australia

  • Local Institution - 0030

    Melbourne, Victoria, Australia

  • Local Institution - 0109

    Traralgon, Victoria, Australia

  • Local Institution - 0106

    Nedlands, Western Australia, Australia

  • Local Institution - 0161

    Nedlands, Western Australia, Australia

  • Local Institution - 0027

    Graz, Austria

  • Local Institution - 0029

    Salzburg, Austria

  • Local Institution - 0168

    Sankt Pölten, Austria

  • Local Institution - 0037

    Vienna, Austria

  • Local Institution - 0072

    Brussels, Belgium

  • Local Institution - 0078

    Charleroi, Belgium

  • Local Institution - 0016

    Liège, Belgium

  • Local Institution - 0177

    Fortaleza, Ceará, Brazil

  • Local Institution - 0180

    Vitória, Espírito Santo, Brazil

  • Local Institution - 0107

    Belo Horizonte, Minas Gerais, Brazil

Showing 40 of 149 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.